PT - JOURNAL ARTICLE AU - Desai, Trishna A AU - Hedman, Åsa K AU - Dimitriou, Marios AU - Koprulu, Mine AU - Figiel, Sandy AU - Yin, Wencheng AU - Johansson, Mattias AU - Watts, Eleanor L AU - Atkins, Joshua R AU - Sokolov, Aleksandr V AU - Schiöth, Helgi B AU - Gunter, Marc J AU - Tsilidis, Konstantinos K AU - Martin, Richard M AU - Pietzner, Maik AU - Langenberg, Claudia AU - Mills, Ian G AU - Lamb, Alastair D AU - Mälarstig, Anders AU - Key, Tim J AU - The PRACTICAL Consortium AU - Travis, Ruth C AU - Smith-Byrne, Karl TI - Identifying proteomic risk factors for overall, aggressive and early onset prostate cancer using Mendelian randomization and tumor spatial transcriptomics AID - 10.1101/2023.09.21.23295864 DP - 2023 Jan 01 TA - medRxiv PG - 2023.09.21.23295864 4099 - http://medrxiv.org/content/early/2023/09/22/2023.09.21.23295864.short 4100 - http://medrxiv.org/content/early/2023/09/22/2023.09.21.23295864.full AB - Background Understanding the role of circulating proteins in prostate cancer risk can reveal key biological pathways and identify novel targets for cancer prevention.Methods We investigated the association of 2,002 genetically predicted circulating protein levels with risk of prostate cancer overall, and of aggressive and early onset disease, using cis-pQTL Mendelian randomization (MR) and colocalization. Findings for proteins with support from both MR, after correction for multiple-testing, and colocalization were replicated using two independent cancer GWAS, one of European and one of African ancestry. Proteins with evidence of prostate-specific tissue expression were additionally investigated using spatial transcriptomic data in prostate tumor tissue to assess their role in tumor aggressiveness. Finally, we mapped risk proteins to drug and ongoing clinical trials targets.Results We identified 20 proteins genetically linked to prostate cancer risk (14 for overall [8 specific], 7 for aggressive [3 specific], and 8 for early onset disease [2 specific]), of which a majority were novel and replicated. Among these were proteins associated with aggressive disease, such as PPA2 [Odds Ratio (OR) per 1 SD increment = 2.13, 95% CI: 1.54-2.93], PYY [OR = 1.87, 95% CI: 1.43-2.44] and PRSS3 [OR = 0.80, 95% CI: 0.73-0.89], and those associated with early onset disease, including EHPB1 [OR = 2.89, 95% CI: 1.99-4.21], POGLUT3 [OR = 0.76, 95% CI: 0.67-0.86] and TPM3 [OR = 0.47, 95% CI: 0.34-0.64]. We confirm an inverse association of MSMB with prostate cancer overall [OR = 0.81, 95% CI: 0.80-0.82], and also find an inverse association with both aggressive [OR = 0.84, 95% CI: 0.82-0.86] and early onset disease [OR = 0.71, 95% CI: 0.68-0.74]. Using spatial transcriptomics data, we identified MSMB as the genome-wide top-most predictive gene to distinguish benign regions from high grade cancer regions that had five-fold lower MSMB expression. Additionally, ten proteins that were associated with prostate cancer risk mapped to existing therapeutic interventions.Conclusion Our findings emphasize the importance of proteomics for improving our understanding of prostate cancer etiology and of opportunities for novel therapeutic interventions. Additionally, we demonstrate the added benefit of in-depth functional analyses to triangulate the role of risk proteins in the clinical aggressiveness of prostate tumors. Using these integrated methods, we identify a subset of risk proteins associated with aggressive and early onset disease as priorities for investigation for the future prevention and treatment of prostate cancer.Competing Interest StatementAnders Malarstig, Asa Hedman, and Marios Dimitriou are employees of Pfizer Inc.Funding StatementThis work was supported by Cancer Research UK (grant no. C8221/A29017). TAD is supported by a Cancer Research UK studentship grant number (C8221/A30904). KSB is supported by Cancer Research UK (grant nos. C8221/A29017 and C16077/A29186) and UKRI grant no. 10063259. ELW is supported by the Intramural Research Program of the National Institutes of Health (NIH). RMM is a National Institute for Health Research Senior Investigator (NIHR202411). RMM is supported by a Cancer Research UK 25 (C18281/A29019) program grant (the Integrative Cancer Epidemiology Program). RMM is also supported by the NIHR Bristol Biomedical Research Centre which is funded by the NIHR and is a partnership between University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. RMM is affiliated with the Medical Research Council Integrative Epidemiology Unit at the University of Bristol which is supported by the Medical Research Council (MC_UU_00011/1, MC_UU_00011/3, MC_UU_00011/6, and MC_UU_00011/4) and the University of Bristol. Sandy Figiel is funded by the The Hanson Trust.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Exposure data were obtained from publicly available data already published and cited. Outcome data were obtained from application and approval from the PRACTICAL Consortium to be used in this work, and from publicly available data already published.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesExposure data are publicly available through previously published and cited papers. Outcome data are available upon application and approval from the PRACTICAL Consortium.